Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles P Sparrow

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
Therapeutic Advances in Gastroenterology|May 19, 2018
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directionsMark G Ward, Miles P Sparrow, Xavier Roblin
World Journal of Gastroenterology|November 4, 2015
How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Mark G Ward, Peter M Irving, Miles P Sparrow
Expert Opinion on Drug Safety|September 2, 2008
Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinolRupert Wl Leong, Richard B Gearry, Miles P Sparrow
Current Gastroenterology Reports|November 12, 2009
Optimizing conventional therapies for inflammatory bowel diseaseMiles P Sparrow, Peter M Irving, Stephen B Hanauer
Internal Medicine Journal|May 8, 2023
Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levelsKathryn Gazelakis, Isabel Chu, Catherine Martin, et al.
Inflammatory Bowel Diseases|October 16, 2010
Optimizing thiopurine therapy in inflammatory bowel diseaseJean-Baptiste Chevaux, Laurent Peyrin-Biroulet, Miles P Sparrow
International Journal of Rheumatic Diseases|March 13, 2014
The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disordersAntony B Friedman, Miles P Sparrow, Peter R Gibson
Current Drug Targets|September 16, 2014
Optimizing conventional medical therapies in inflammatory bowel disease in 2014Anil Kumar Asthana, Miles P Sparrow, Laurent Peyrin-Biroulet
Case Reports in Gastroenterology|February 21, 2025
Anaphylaxis to a Vedolizumab Infusion following Drug Holiday in a Patient with Ulcerative Colitis: A Case ReportJadon Karp, Henry Shen, Thomas Goodwin, et al.
Internal Medicine Journal|August 4, 2021
E-Health and remote management of patients with inflammatory bowel disease: lessons from Denmark in a time of needDorit V Ankersen, Savannah Noack, Pia Munkholm, et al.
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
Therapeutic Advances in Gastroenterology|May 19, 2018
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directionsMark G Ward, Miles P Sparrow, Xavier Roblin
World Journal of Gastroenterology|November 4, 2015
How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Mark G Ward, Peter M Irving, Miles P Sparrow
Expert Opinion on Drug Safety|September 2, 2008
Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinolRupert Wl Leong, Richard B Gearry, Miles P Sparrow
Current Gastroenterology Reports|November 12, 2009
Optimizing conventional therapies for inflammatory bowel diseaseMiles P Sparrow, Peter M Irving, Stephen B Hanauer
Internal Medicine Journal|May 8, 2023
Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levelsKathryn Gazelakis, Isabel Chu, Catherine Martin, et al.
Inflammatory Bowel Diseases|October 16, 2010
Optimizing thiopurine therapy in inflammatory bowel diseaseJean-Baptiste Chevaux, Laurent Peyrin-Biroulet, Miles P Sparrow
International Journal of Rheumatic Diseases|March 13, 2014
The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disordersAntony B Friedman, Miles P Sparrow, Peter R Gibson
Current Drug Targets|September 16, 2014
Optimizing conventional medical therapies in inflammatory bowel disease in 2014Anil Kumar Asthana, Miles P Sparrow, Laurent Peyrin-Biroulet
Case Reports in Gastroenterology|February 21, 2025
Anaphylaxis to a Vedolizumab Infusion following Drug Holiday in a Patient with Ulcerative Colitis: A Case ReportJadon Karp, Henry Shen, Thomas Goodwin, et al.
Internal Medicine Journal|August 4, 2021
E-Health and remote management of patients with inflammatory bowel disease: lessons from Denmark in a time of needDorit V Ankersen, Savannah Noack, Pia Munkholm, et al.
Pageof 10